

3rd November, 2021

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Update on intimations dated 13th November, 2018 and 8th February, 2019 on acquisition agreement entered between InvaGen Pharmaceuticals Inc. and Avenue Therapeutics Inc.

Dear Sir/Madam,

In reference to the above mentioned intimations, Company's wholly owned step down subsidiary, InvaGen Pharmaceuticals Inc. ("InvaGen"), USA had entered into a Stock Purchase and Merger Agreement ("the SPMA") for acquisition of Avenue Therapeutics Inc. ("Avenue"), a company focused on the development and commercialization of intravenous (IV) Tramadol.

Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice of termination from Avenue. InvaGen is evaluating the notice for any further steps that it may be required to take in this regard.

The existing shareholding of InvaGen in Avenue shall continue.

This is for your information and record.

Thankyou

Yours Faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode